All Posts By

laurabbook@gmail.com

OncLive
Distinct Genomic Profile of Lung Cancer in Never Smokers Comes Into Focus ResearchTreatments

Distinct Genomic Profile of Lung Cancer in Never Smokers Comes Into Focus

*February 2022* A growing recognition of the distinct clinical, pathological, and biological features of lung cancers that arise in nonsmokers is fostering greater interest in examining the molecular underpinnings of lung cancer in this patient subset. During the past 2 decades, the treatment of patients with lung cancer has undergone…
laurabbook@gmail.com
June 29, 2022
OncLive
ODAC Recommends New Trial Data of Sintilimab in US Population of Frontline NSCLC ResearchTreatments

ODAC Recommends New Trial Data of Sintilimab in US Population of Frontline NSCLC

*February 2022* The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application (BLA) for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer (NSCLC). ODAC concluded that supporting data from the phase…
laurabbook@gmail.com
June 29, 2022
Future Medicine
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance ResearchTreatments

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

*December 2021* Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called EGFR. Although tumors will usually shrink (respond) during treatment with osimertinib, they can stop responding, or become resistant, to osimertinib. A common cause of resistance is ‘MET amplification’, which…
laurabbook@gmail.com
June 29, 2022
Lisa Goldman blog
The Not Really Terminal Terminal Patient Put in the Wrong Terminal Coping With Cancer

The Not Really Terminal Terminal Patient Put in the Wrong Terminal

*February 2022* By Lisa Goldman, lung cancer survivor Have you ever gone to the airport to catch a flight to another country and you arrive at the international terminal only to discover you’re in the wrong place, apparently your international flight isn’t “international enough” to qualify for the international terminal.…
laurabbook@gmail.com
March 23, 2022
EGFR Resisters logo
EGFR Resisters Grief and Coping Zoom Session with CancerCare Grief Counselor Coping With Cancer

EGFR Resisters Grief and Coping Zoom Session with CancerCare Grief Counselor

*December 2021* We have lost a fair number of people in our group recently which has taken an emotional toll on many of us. The LCRF responded to our needs by scheduling a zoom session on December 9th with Win Boerckel, MSW, MBA, LCSW-R, CancerCare's Long Island Director of Social Service.…
laurabbook@gmail.com
March 23, 2022
2022 Targeted Therapies Logo
Slide Decks from the 2022 Targeted Therapies Meeting ResearchTreatments

Slide Decks from the 2022 Targeted Therapies Meeting

*February 2022* Open Questions Around First-Line Treatment for EGFR Mutant Lung Cancers, Dr Helena Yu, presenter Acquired Resistance to EGFR TKIs, Dr. Katerina Politi, presenter Histological transformation and off target mechanisms are frequently identified on disease progression for patients with EGFRmutant lung cancer treated with first-line osimertinib, Dr. Noura Choudhury,…
laurabbook@gmail.com
March 18, 2022
Lung Cancer Journal
Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers ResearchTreatments

Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers

*January 2022* Highlights: p53 and Rb alterations are confirmed as predisposing to SCLC transformation in EGFR- LUAD. Paired EGFR-LUAD/SCLC samples showed diverse clonal evolution patterns. TERT amplification is an acquired event during EGFR-LUAD to SCLC transformation. Introduction Among the different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs)…
laurabbook@gmail.com
March 18, 2022